Physician profile
William Josephson
NPI 1376647651
$7,466.23
in general payments reported to CMS, 2019-2025
36 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $1,281 · 2021: $1,375 · 2022: $1,106 · 2023: $765 · 2024: $1,295 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,506.41 | 2019-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $730.82 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $510.38 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $464.53 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Pfizer INC. | $448.79 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $430.25 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.47 | 2020-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $344.05 | 2020-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $291.14 | 2019-2023 | |
| Amgen INC. | $238.65 | 2022-2025 | Evenity, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $238.42 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $236.13 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $225.82 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $199.93 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $167.25 | 2024-2025 | Ingrezza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $146.53 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $143.93 | 2021-2022 | |
| Glaxosmithkline, LLC. | $129.47 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $108.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $75.25 | 2020-2025 | Eliquis |
| Abbvie INC. | $62.53 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $57.50 | 2025 | Vowst, Zenpep |
| Otsuka America Pharmaceutical, INC. | $55.54 | 2023-2024 | Rexulti |
| Mannkind Corporation | $44.16 | 2020 | |
| Sun Pharmaceutical Industries INC. | $35.48 | 2021 | |
| Indivior INC. | $35.37 | 2021 | |
| Janssen Scientific Affairs, LLC | $32.50 | 2021 | |
| Ascendis Pharma Endocrinology INC | $25.07 | 2025 | Yorvipath |
| Corcept Therapeutics | $22.00 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $20.79 | 2021 | |
| Ibsa Pharma INC. | $20.58 | 2020 | |
| Eisai INC. | $19.87 | 2025 | |
| Merck Sharp & Dohme LLC | $17.38 | 2020 | |
| Dexcom, INC. | $17.34 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $14.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Josephson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.